<DOC>
	<DOCNO>NCT01268059</DOCNO>
	<brief_summary>The purpose study evaluate dose , antitumor activity , safety pharmacology MEDI-575 combination carboplatin/paclitaxel subject previously untreated , advance non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Carboplatin Paclitaxel With Without MEDI-575 Adults With Previously Untreated , Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion Criteria 1 . Age 18 year old ( 20 year old subject Japanese cohort ) time screen 2 . Written inform consent locally require authorization ( eg , HIPAA USA , EU Data Privacy Directive EU ) obtain subject/legal representative prior performing protocolrelated procedure , include screen evaluation 3 . Histologically confirm inoperable Stage IIIB Stage IV nonsmall cell lung cancer accord Seventh Edition American Joint Committee Cancer ( AJCC ) Tumor Node Metastases ( TNM ) stag system ( subject squamous cell carcinoma enrol ) 4 . ECOG PS 0 1 ( see , Appendix 2 ) 5 . Life expectancy ≥ 3 month 6 . Prothrombin time elevation ≤ Grade 2 National Cancer Institute Common Toxicity Criteria Adverse Events ( NCI CTCAE ) criterion ( Version 4.0 ) acceptable subject anticoagulant therapy 7 . Adequate hematologic function define : 8 . Hemoglobin ≥ 9 g/dL 9 . Absolute neutrophil count ( ANC ) ≥ 1500/mm3 10 . Platelet count ≥ 100,000/mm3 11 . Adequate organ function define follow : 12 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 5 × institutional upper limit normal ( ULN ) case involve liver metastasis ≤ 2 × institutional ULN case 13 . Bilirubin ≤ 1.5 × ULN except case subject document suspect Gilbert 's disease ≤ 5 × ULN 14 . Calculated creatinine clearance ( CrCl ) ≥ 50 mL/min determine CockroftGault equation ( Cockroft Gault , 1976 ) 15 . Suitable candidate therapy carboplatin/paclitaxel 16 . Subjects must least 1 lesion measurable use RECIST ( v1.1 ) . Other nonmeasurable lesion allow . 17 . Subjects must willing consent allow collection archive NSCLC tumor sample 18 . Negative serum betahuman chorionic gonadotropin ( βhCG ) test ( woman childbearing potential ) 19 . Females childbearing potential , unless surgically sterile ( ie , bilateral tubal ligation , bilateral oophorectomy , complete hysterectomy ) , sterile male partner , premenarchal least 2 year postmenopausal , practice abstinence , must use 2 effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , use condom spermicide sexual partner ) screening , must agree continue use precaution 90 day final dose treatment ; cessation birth control point discuss responsible physician 20 . Males , unless surgically sterile , must use 2 effective method birth control female partner must agree continue use contraceptive precaution screen 90 day final dose treatment 21 . Normal potassium baseline 22 . Normal magnesium baseline Exclusion Critieria Any follow would exclude subject participation study : 1 . Any condition , opinion investigator , would interfere evaluation treatment interpretation subject safety study result 2 . Concurrent enrollment another clinical study 3 . Employees clinical study site individual involve conduct study , immediate family member individual 4 . Any concurrent chemotherapy , radiotherapy , immunotherapy , biologic , hormonal therapy treatment cancer 5 . Previous mAb treatment specifically direct PDGF PDGF receptor 6 . History serious allergy reaction component MEDI575 formulation 7 . Receipt previous systemic anticancer therapy advance metastatic disease include chemotherapy regimen , hormonal therapy , TKIs , radiotherapy , investigational agent , biological immunological base therapy ( include , limited mAb therapy bevacizumab ) 8 . Previous adjuvant/neoadjuvant radiotherapy chemotherapy treatment previous nonmetastatic disease allow provided 6 month elapse end therapy time enrollment . 9 . New York Heart Association ≥ Class II congestive heart failure ( see Appendix 3 ) MedImmune Protocol CDONMEDI5751031 10 . History myocardial infarction , unstable angina , transient ischemic attack stroke within previous 6 month prior enrollment 11 . History invasive malignancy within 5 year except cervical carcinoma situ ( CIS ) , nonmelanomatous carcinoma skin ductal carcinoma situ ( DCIS ) breast surgically cure 12 . Evidence active infection require use systemic antimicrobial treatment within 72 hour prior initial treatment MEDI575 13 . Use immunosuppressive medication ( inhaled topical corticosteroid permit ) within 7 day prior enrollment 14 . Systemic immunosuppressive steroid therapy . Subjects may take replacement dos steroid ( define ≤ 30 mg day hydrocortisone equivalent ) stable dose least 2 week prior enrollment 15 . History active human immunodeficiency virus ( HIV ) active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection 16 . Pregnancy lactation 17 . Previous medical history evidence intercurrent illness may , opinion investigator , compromise safety subject study 18 . Clinically significant abnormality ECG 19 . Any physical , social , psychiatric condition would prevent effective cooperation participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>